Skip to Content

Kazano Approval History

  • FDA approved: Yes (First approved January 25th, 2013)
  • Brand name: Kazano
  • Generic name: alogliptin and metformin
  • Dosage form: Tablets
  • Company: Takeda Pharmaceutical Company Limited
  • Treatment for: Diabetes, Type 2

Kazano (alogliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide antihyperglycemic fixed-dose combination for the treatment of type 2 diabetes.

Development History and FDA Approval Process for Kazano

Jan 25, 2013Approval Takeda Receives FDA Approval for Kazano (alogliptin and metformin) for Type 2 Diabetes
Nov 28, 2011Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.